NSE மற்றும் BSE-யின் ஒவ்வொரு கார்ப்பரேட் அறிவிப்பும், AI-யால் சில நிமிடங்களில் படிக்கப்பட்டு விளக்கப்படுகிறது — தாக்கம், முக்கிய புள்ளிவிவரங்கள், குறுகிய/நீண்டகாலப் பார்வை, கவனிக்க வேண்டியவை.
குறிப்பு: இவை NSE பொது அறிக்கைகளின் AI-உருவாக்கிய, கல்வி நோக்கச் சுருக்கங்கள் — ஒவ்வொரு ஆவணத்தையும் ஆதாரமாகக் கொண்டவை, ஆனால் முதலீட்டு ஆலோசனை அல்ல, மேலும் முழுமையற்றதாகவும் இருக்கலாம். அசல் அறிக்கையுடன் சரிபார்க்கவும், செயல்படுவதற்கு முன் SEBI-பதிவு பெற்ற முதலீட்டு ஆலோசகரை அணுகவும்.
Paramount Communications FY26 Revenue Rises 23% to ₹1,912 Cr; Annual PBT Declines to ₹81 Cr
Paramount Communications reported a strong 23% year-on-year growth in annual revenue, reaching ₹1,912.16 crore for FY26. However, the company's full-year Profit Before Tax (PBT) saw a decline to ₹81.31 crore from ₹110.60 crore in the previous year, impacted by rising finance and operational costs. Quarterly performance showed resilience with Q4 FY26 revenue at ₹573.30 crore, up from ₹504.85 crore YoY. The board also approved the re-appointment of internal and cost auditors for the 2026-27 fiscal year.
முக்கிய அம்சங்கள்
Annual Revenue from operations grew 22.8% YoY to ₹1,912.16 crore in FY26.Full-year Profit Before Tax (PBT) decreased by 26.5% to ₹81.31 crore compared to ₹110.60 crore in FY25.Finance costs nearly doubled during the year, rising from ₹10.87 crore to ₹21.03 crore.Q4 FY26 Revenue showed a 13.6% YoY increase, reaching ₹573.30 crore.Other Income for the full year jumped significantly to ₹51.77 crore from ₹12.83 crore in the previous fiscal.
👀 கவனிக்க வேண்டியவை
Investors should monitor the company's ability to manage rising finance costs and operating expenses, which are currently offsetting healthy revenue growth. While the top-line expansion is positive, the compression in annual profit margins warrants a cautious approach.
Paradeep Phosphates Limited has received a favorable rectification order from the Income Tax Department for Assessment Year 2020-21. The Assistant Commissioner of Income Tax has quashed a previously raised tax demand of ₹20.61 crore and granted a refund of ₹20.57 crore to the company. This resolution follows a dispute regarding the adjustment of carry-forward losses and MAT credits. The outcome is a significant positive for the company's cash flow and removes a material legal uncertainty.
முக்கிய அம்சங்கள்
Income Tax demand of ₹20.61 crore for AY 2020-21 has been officially quashed.The company has been granted a tax refund amounting to ₹20.57 crore.The order was passed under Section 154 of the Income-tax Act, 1961, by the ACIT, Bhubaneswar.The dispute involved adjustments related to carry-forward losses and MAT credits from earlier years.
👀 கவனிக்க வேண்டியவை
Investors should view this as a positive development that strengthens the balance sheet and improves liquidity. No further action is required as the litigation has reached a favorable conclusion.
Park Medi World Incorporates Step-Down Subsidiary Healplus Medical Services for Expansion
Park Medi World Limited has announced the incorporation of a new step-down subsidiary, Healplus Medical Services Private Limited, through its 81.81% owned subsidiary Park Medicenters and Institutions Private Limited. The new entity is a wholly-owned subsidiary of Park Medicenters and was incorporated on May 20, 2026, with an initial capital infusion of INR 0.01 crore. This new unit will focus on the retail and wholesale distribution of pharmaceuticals, medical goods, and healthcare products. The move is strategically aimed at diversifying the company's current healthcare operations into the pharmacy and wellness retail segments.
முக்கிய அம்சங்கள்
Incorporated 'Healplus Medical Services Private Limited' as a wholly-owned step-down subsidiary on May 20, 2026Parent company Park Medi World holds 81.81% equity in the immediate subsidiary, Park MedicentersInitial cost of acquisition and capital infusion is set at INR 0.01 crore in cashBusiness focus includes retail, wholesale, and distribution of pharmaceuticals, surgical goods, and wellness productsStrategic objective is to diversify and expand existing healthcare business operations through new outlets and pharmacies
👀 கவனிக்க வேண்டியவை
Investors should monitor the scaling of this new retail pharmacy and distribution arm as it represents a vertical integration strategy. While the initial investment is small, successful execution could provide a steady secondary revenue stream alongside hospital operations.
SPARC Partner Receives US FDA CRL for PDP-716 NDA Over Manufacturing Issues
Sun Pharma Advanced Research Company (SPARC) announced that its licensing partner, Ocuvex Therapeutics Inc., has received a Complete Response Letter (CRL) from the US FDA for the PDP-716 New Drug Application. The CRL was issued specifically due to inspection findings at the finished product manufacturing facility, rather than clinical or safety concerns. While the FDA did not raise any other issues with the NDA, this development delays the potential commercialization and revenue generation from this product. Investors should note that the path to approval now depends on the successful remediation of the manufacturing facility's deficiencies.
முக்கிய அம்சங்கள்
US FDA issued a Complete Response Letter (CRL) for the PDP-716 New Drug Application (NDA).The CRL is attributed to inspection findings at the finished product manufacturing facility.FDA confirmed no other issues or deficiencies were raised regarding the PDP-716 NDA itself.The licensing partner involved in the US market for this drug is Ocuvex Therapeutics Inc.Approval and subsequent launch of PDP-716 will be delayed until manufacturing issues are resolved.
👀 கவனிக்க வேண்டியவை
Investors should monitor for updates regarding the remediation of the manufacturing facility and the timeline for a potential resubmission to the FDA. The stock may face short-term pressure due to the delay in expected milestone or royalty income.
SPARC Allots 3.85 Crore Warrants to Raise Up to ₹600 Crore on Preferential Basis
Sun Pharma Advanced Research Company Limited (SPARC) has approved the allotment of 3,85,10,000 warrants to Shanghvi Finance Private Limited on a preferential basis. The warrants are issued at a price of INR 155.80 each, bringing the total potential fundraise to approximately INR 600 crore. The company has received an upfront payment of INR 149.99 crore, which constitutes 25% of the total warrant issue price. Each warrant is convertible into one equity share of face value INR 1, which will lead to equity dilution upon conversion.
முக்கிய அம்சங்கள்
Allotment of 3,85,10,000 warrants to promoter group entity Shanghvi Finance Private Limited.Warrants issued at a price of INR 155.80 per warrant, totaling a potential fundraise of ~INR 600 crore.Upfront receipt of INR 149.99 crore, representing 25% of the total warrant issue price.Each warrant is convertible into one fully paid-up equity share of face value INR 1 within regulatory timelines.
👀 கவனிக்க வேண்டியவை
Investors should view this capital infusion positively as it provides SPARC with essential funding for its research and development pipeline. However, shareholders should keep in mind the impending equity dilution when these warrants are converted into shares.
📊 கடந்த 7 நாட்கள் — உணர்வு அடிப்படையில் பகுப்பாய்வு செய்யப்பட்ட அறிவிப்புகள்
SPARC Reports Massive Q4 Profit of ₹1,761 Cr Driven by ₹1,840 Cr PRV Monetization
SPARC reported a massive turnaround in Q4 FY26 with a net profit of ₹1,760.7 crore, compared to a loss of ₹61 crore in the same period last year. This surge is primarily attributed to the recognition of ₹1,840 crore in revenue from a Priority Review Voucher (PRV) granted by the USFDA for Sezaby®, which was sold for $195 million. For the full financial year 2026, the company posted a profit of ₹1,552 crore against a loss of ₹345 crore in FY25. This one-time windfall significantly boosts the company's cash reserves and equity position.
முக்கிய அம்சங்கள்
Net Profit of ₹1,760.7 crore in Q4 FY26 vs a loss of ₹61 crore in Q4 FY25Recognized ₹1,840 crore in other operating revenue from the sale of a USFDA Priority Review VoucherFull-year FY26 profit stands at ₹1,552 crore compared to a loss of ₹345 crore in FY25Total income for the quarter surged to ₹1,855 crore from just ₹27 crore YoYEarnings Per Share (EPS) for the quarter jumped to ₹54.26 from a negative ₹1.88 YoY
👀 கவனிக்க வேண்டியவை
Investors should recognize this as a significant one-time windfall that provides SPARC with substantial capital to fund its expensive R&D pipeline. While the core research business remains loss-making, the strengthened balance sheet reduces immediate dilution risks.
BIL Vyapar Limited Schedules 11th Committee of Creditors Meeting for May 19, 2026
BIL Vyapar Limited, formerly known as Binani Industries Limited, has announced the 11th meeting of its Committee of Creditors (CoC) scheduled for May 19, 2026. The company is currently undergoing the Corporate Insolvency Resolution Process (CIRP) under the Insolvency and Bankruptcy Code. This meeting is a critical step in the ongoing legal efforts to resolve the company's debt and determine its future viability. Equity shareholders should remain cautious as insolvency proceedings often result in significant restructuring or liquidation.
முக்கிய அம்சங்கள்
11th meeting of the Committee of Creditors (CoC) to be held on May 19, 2026.Company is currently under the Corporate Insolvency Resolution Process (CIRP).Disclosure made pursuant to Regulation 30 and Para 16(g) of SEBI LODR Regulations.BIL Vyapar Limited was formerly known as Binani Industries Limited (NSE: BILVYAPAR).
👀 கவனிக்க வேண்டியவை
Investors should exercise extreme caution as equity value is typically at high risk during insolvency proceedings. Monitor for updates regarding any approved resolution plans or liquidation orders.
Paramount Communications to Raise ₹92.4 Cr via Preferential Issue; EGM on June 06
Paramount Communications (PARACABLES) has called an Extraordinary General Meeting (EGM) on June 06, 2026, to approve a significant fundraise. The company proposes to issue approximately 2.2 crore equity shares at ₹42 per share, totaling ₹92.40 crores, alongside convertible warrants. Marquee institutional investors including Abakkus Diversified Alpha Fund (Sunil Singhania's fund) and Subhkam Ventures are the primary participants in this preferential allotment.
முக்கிய அம்சங்கள்
Issuance of up to 2,19,97,664 equity shares at a price of ₹42 per share (including ₹40 premium).Total equity fundraise estimated at ₹92.40 crores from non-promoter investors.Abakkus Diversified Alpha Fund and its second series are the lead investors, contributing ₹50 crores.Other notable participants include Subhkam Ventures (₹10 Cr) and Singularity Equity Fund II (₹5 Cr).The relevant date for floor price calculation was fixed as May 07, 2026.
👀 கவனிக்க வேண்டியவை
The participation of marquee investors like Abakkus suggests strong institutional confidence in the company's growth trajectory. Investors should view this as a positive development for long-term capital structure, while keeping an eye on the dilution impact.
Park Medi World FY26 PAT Jumps 27% to ₹274 Cr; Bed Capacity to Reach 5,460 by 2028
Park Medi World reported its strongest financial year in FY26, with revenue growing 21% to ₹1,679 crores and PAT rising 27% to ₹274 crores. The company significantly expanded its footprint by adding 610 beds, entering new markets in Uttar Pradesh and Punjab, reaching a total capacity of 3,610 beds by year-end. Operational efficiency improved with occupancy rising to 64.1% and ARPOB increasing to ₹28,000. The balance sheet was substantially deleveraged, with gross debt falling from ₹450 crores to just ₹28 crores, providing a strong foundation for future growth.
முக்கிய அம்சங்கள்
Annual revenue grew 21% YoY to ₹1,679 crores with a healthy EBITDA margin of 26%Net profit increased by 27% to ₹274 crores, while ROCE and ROE stood at 18% and 20% respectivelyAdded 610 beds in FY26 via new units in Bathinda and Agra; total operational beds reached 3,960 by May 2026Gross debt drastically reduced from ₹450 crores to ₹28 crores, with plans for full repayment in Q1 FY27Targeting a total capacity of 5,460 beds by March 2028, supported by ₹329 crores in operating cash flow
👀 கவனிக்க வேண்டியவை
Investors should take note of the company's aggressive deleveraging and clear roadmap to increase bed capacity by nearly 50% by 2028. The stock remains a strong growth play in the North Indian healthcare sector given its high capital efficiency and improving ARPOB.
Par Drugs and Chemicals Limited reported its audited financial results for the fiscal year ended March 31, 2026, maintaining a debt-free balance sheet. Total equity grew to ₹111.98 crore from ₹98.97 crore in the previous year, while cash and cash equivalents surged to ₹41.84 crore. A key strategic move includes the board's authorization to invest up to ₹90 crore of surplus funds into liquid and arbitrage instruments. The company also reported a significant reduction in trade receivables, indicating improved collection cycles.
முக்கிய அம்சங்கள்
Total Equity increased by 13.1% year-on-year to ₹111.98 crore as of March 31, 2026.Company remains debt-free with zero long-term and short-term borrowings.Cash and cash equivalents grew by 51.7% to ₹41.84 crore from ₹27.58 crore.Board authorized a new investment limit of ₹90 crore for surplus funds in liquid and arbitrage funds.Trade receivables improved significantly, dropping to ₹12.03 crore from ₹16.71 crore year-on-year.
👀 கவனிக்க வேண்டியவை
The company's strong cash position and debt-free status provide a solid margin of safety. Investors should monitor the deployment of the ₹90 crore surplus for potential future expansions or acquisitions.
Parag Milk Foods FY26 Revenue Hits ₹3,800 Cr; New Age Business Grows 91%
Parag Milk Foods reported a strong FY26 with annual revenue crossing ₹3,800 crores and a 5% overall volume growth. The company's New Age business, comprising Avvatar and Pride of Cows, saw a massive 91% growth, now contributing 10% to total revenue. Despite a 15% YoY increase in milk prices to ₹42/litre, Q4 gross margins improved to 28% through better product mix and pricing discipline. Management aims for the New Age segment to reach 20-25% of total revenue within the next 3-5 years.
முக்கிய அம்சங்கள்
Annual revenue crossed ₹3,800 crores with core category volume growth of 8%New Age business (Avvatar & Pride of Cows) revenue grew 91% YoY, reaching ₹100 crores per quarterQ4 gross margins expanded to 28% despite average milk prices rising 15% YoY to ₹42 per litreAvvatar holds a 14-15% market share in the protein segment across quick commerce and marketplacesPlanned cheese capacity expansion from 60 metric tons to 80 metric tons to meet growing demand
👀 கவனிக்க வேண்டியவை
Investors should focus on the rapid scaling of the high-margin Avvatar brand and the company's successful premiumization strategy. The transition toward a 25% revenue contribution from the New Age segment suggests a structural improvement in long-term profitability.
Paramount Communications to Raise ₹122.64 Crore via Preferential Issue of Shares and Warrants
Paramount Communications (PARACABLES) has approved a significant fundraise of approximately ₹122.64 crores through a preferential allotment. The company will issue 2.20 crore equity shares to non-promoter investors, including reputable funds like Abakkus Diversified Alpha Fund, at ₹42 per share. Additionally, 72 lakh convertible warrants will be issued to promoters at the same price, with 25% payable upfront. This capital infusion is intended to strengthen the balance sheet and support future growth initiatives.
முக்கிய அம்சங்கள்
Preferential issue of 2,19,97,664 equity shares at ₹42 per share, aggregating to ₹92.40 crores.Issuance of 72,00,000 convertible warrants to promoters at ₹42 per warrant, totaling ₹30.24 crores.Major participation from Abakkus Diversified Alpha Fund schemes, contributing approximately ₹50 crores.Issue price of ₹42 is slightly above the regulatory floor price of ₹41.68 per share.Promoter holding to adjust from 49.14% to 47.01% upon full conversion of warrants and equity issuance.
👀 கவனிக்க வேண்டியவை
The participation of high-profile institutional investors like Abakkus is a strong positive signal regarding the company's valuation and growth potential. Investors should monitor the EGM on June 6, 2026, for final approval and subsequent updates on fund utilization.
Parsvnath Developers Enters Corporate Insolvency Resolution Process (CIRP)
Parsvnath Developers Limited has officially entered the Corporate Insolvency Resolution Process (CIRP) following an order from the NCLT New Delhi Bench. The insolvency commencement date was April 30, 2026, with Manoj Kumar Anand appointed as the Interim Resolution Professional (IRP). The resolution process is estimated to conclude by October 27, 2026, within the standard 180-day window. Creditors, including all real estate allottees, have been directed to submit their claims by May 27, 2026.
முக்கிய அம்சங்கள்
NCLT New Delhi ordered CIRP commencement on April 30, 2026, under Petition No. (IB) 468/PB/2024Manoj Kumar Anand appointed as Interim Resolution Professional (IRP) to manage the company's affairsEstimated date of closure for the insolvency resolution process is October 27, 2026Last date for creditors and real estate allottees to submit claims is May 27, 2026The company's board is effectively suspended as the IRP takes control of management
👀 கவனிக்க வேண்டியவை
Equity shareholders should exercise extreme caution as insolvency proceedings typically result in significant erosion of equity value. Investors should monitor the resolution plan and the IRP's progress, but be prepared for potential trading suspensions or delisting.
Paras Defence Re-appoints Auditors and Recommends ₹1 Dividend for FY26
Paras Defence and Space Technologies announced its board meeting outcomes for the fiscal year ended March 31, 2026. The company recommended a final dividend of ₹1 per equity share (20% of face value) and approved the audited financial results for the year. Additionally, the board approved the re-appointment of M/s S M L and Co. LLP as Internal Auditors and M/s Dinesh Jain & Company as Cost Auditors for FY 2026-27. The statutory auditors provided an unmodified opinion on the company's financial statements, indicating no major accounting discrepancies.
முக்கிய அம்சங்கள்
Recommended a final dividend of ₹1 per equity share of ₹5 each for FY 2025-26Re-appointed M/s S M L and Co. LLP as Internal Auditors for the financial year 2026-27Re-appointed M/s Dinesh Jain & Company as Cost Auditor for the financial year 2026-27Statutory Auditors Chaturvedi & Shah LLP issued an unmodified opinion on FY26 financial results
👀 கவனிக்க வேண்டியவை
Investors should view the auditor re-appointments as a sign of continuity in internal controls. Monitor the upcoming AGM for the dividend record date and detailed financial performance metrics.
Paras Defence Recommends Final Dividend of ₹1 Per Share for FY 2025-26
Paras Defence and Space Technologies Limited has recommended a final dividend of ₹1 per equity share for the financial year ended March 31, 2026. The dividend is calculated on a face value of ₹5 per share, representing a 20% payout. Alongside the dividend, the board approved the audited standalone and consolidated financial results for FY26 with an unmodified audit opinion. The company also confirmed the re-appointment of its internal and cost auditors for the next financial year.
முக்கிய அம்சங்கள்
Recommended a final dividend of ₹1 per equity share of face value ₹5 each for FY 2025-26Approved audited standalone and consolidated financial results for the quarter and year ended March 31, 2026Statutory auditors issued an unmodified opinion on the financial statements, ensuring reporting integrityRe-appointed M/s S M L and Co. LLP as Internal Auditor and M/s Dinesh Jain & Company as Cost Auditor for FY 2026-27
👀 கவனிக்க வேண்டியவை
Investors should track the upcoming Annual General Meeting (AGM) for the announcement of the record date to be eligible for the dividend. The consistent dividend payout reflects management's confidence in the company's financial stability within the high-growth defense sector.
Paras Defence Recommends ₹1 Dividend and Approves Audited FY26 Financial Results
Paras Defence and Space Technologies has approved its audited financial results for the quarter and year ended March 31, 2026. The Board recommended a final dividend of ₹1 per equity share (20% of the ₹5 face value), subject to shareholder approval. The company also re-appointed its internal and cost auditors for the 2026-27 fiscal year. The statutory auditors issued an unmodified opinion, indicating that the financial statements present a true and fair view of the company's performance.
முக்கிய அம்சங்கள்
Recommended a final dividend of ₹1 per equity share of ₹5 face value for FY 2025-26.Approved audited standalone and consolidated financial results for the quarter and year ended March 31, 2026.Statutory auditors (Chaturvedi & Shah LLP) issued an unmodified opinion on the financial results.Re-appointed M/s SML and Co. LLP as Internal Auditors and M/s Dinesh Jain & Company as Cost Auditors for FY 2026-27.
👀 கவனிக்க வேண்டியவை
Investors should review the detailed financial tables for revenue and margin growth trends in the defense sector. The dividend recommendation and clean audit report are positive indicators of corporate governance and cash flow stability.
NCLT Admits Parsvnath Developers into Insolvency Over ₹452 Crore Default
The NCLT New Delhi Bench has admitted Parsvnath Developers into the Corporate Insolvency Resolution Process (CIRP) following a default of ₹452.34 crore. A petition filed by a financial creditor led to the appointment of Mr. Manoj Kumar Anand as the Interim Resolution Professional (IRP). However, the NCLT has temporarily restrained the IRP from taking further steps until a Delhi High Court hearing scheduled for May 25, 2026. The company strongly disputes the debt, claiming total repayments of ₹4,696.01 crore against a disbursed amount of ₹4,153.26 crore.
முக்கிய அம்சங்கள்
NCLT admitted the insolvency petition for a principal default amount of ₹452.34 crore.Mr. Manoj Kumar Anand has been appointed as the Interim Resolution Professional (IRP).Company claims to have already repaid ₹4,696.01 crore, exceeding the disbursed principal of ₹4,153.26 crore.The IRP is currently restrained from taking precipitative steps pending a High Court hearing on May 25, 2026.
👀 கவனிக்க வேண்டியவை
Investors should exercise extreme caution as insolvency proceedings typically lead to significant equity dilution or delisting. Monitor the Delhi High Court proceedings on May 25 for any potential stay on the NCLT order.
Paradeep Phosphates Reports 52% PAT Growth in FY26; Revenue Up 29% to ₹21,826 Cr
Paradeep Phosphates (PPL) delivered a robust performance for FY26, with annual revenue growing 28.7% to ₹2,18,263 million and PAT surging 52.2% to ₹10,008 million. The company achieved its highest-ever annual production of 3.7 MMT, reaching 100% capacity utilization across its plants. Strategic backward integration progressed significantly with the commissioning of new Sulphuric Acid plants at Paradeep and Mangalore, increasing capacity by 45%. Despite a marginal 4.7% YoY dip in Q4 PAT, the overall annual margins improved due to better economies of scale and a shift toward value-added NPK grades.
முக்கிய அம்சங்கள்
FY26 Revenue from Operations increased by 28.7% YoY to ₹2,18,263 million.Annual PAT jumped 52.2% to ₹10,008 million with EBITDA margins expanding to 10.3%.Total fertilizer sales volume grew 10.2% YoY to 4.21 MMT during the full year.Commissioned 0.6 MMTPA of Sulphuric Acid capacity, a 45% increase, to enhance backward integration.Outlined a strategic expansion plan to reach 5.0 MMTPA total capacity by FY29.
👀 கவனிக்க வேண்டியவை
Investors should focus on the company's successful backward integration and its transition toward high-margin NPK products which are driving profitability. The long-term growth outlook remains strong supported by the FY29 capacity expansion roadmap and high capacity utilization.
Park Medi World Limited Releases Q4 & FY26 Audited Financial Results Presentation
Park Medi World Limited has officially released its investor presentation for the audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. This disclosure, made under SEBI Regulation 30, provides the finalized financial performance for the 2026 fiscal year. The presentation follows the company's transition to a public entity after its Red Herring Prospectus filing in December 2024. Investors can now access detailed operational updates and financial metrics for the hospital group through the stock exchange filings.
முக்கிய அம்சங்கள்
Release of audited standalone and consolidated financial results for the full year ended March 31, 2026Formal disclosure compliant with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015The presentation provides a comprehensive overview of the group's performance for the 12-month period of FY26Follows the regulatory framework established during the company's IPO process initiated in late 2024
👀 கவனிக்க வேண்டியவை
Investors should review the full presentation on the company's website to analyze key healthcare sector KPIs such as bed occupancy rates and Average Revenue Per Occupied Bed (ARPOB).
Park Medi World FY26 Net Profit Jumps 27% to ₹2,736 Mn; Bed Capacity Hits 3,960
Park Medi World delivered its strongest financial year to date, with FY26 revenue growing 21% to INR 16,794 million and Net Profit rising 27% to INR 2,736 million. The company significantly expanded its footprint, adding 610 beds through acquisitions in Bhatinda and Agra, and commissioning a 350-bed greenfield facility in Panchkula in April 2026. Operational efficiency improved as debtor days dropped from 161 to 129, while the balance sheet remains robust with negligible debt and INR 5,509 million in cash equivalents. Management is focused on integrating these new assets and scaling to a target of 1,500 additional beds by FY28.
முக்கிய அம்சங்கள்
FY26 Revenue grew 21% YoY to INR 16,794 mn, while Q4 Revenue surged 30% YoY to INR 4,604 mnAnnual Net Profit increased 27% to INR 2,736 mn with margins expanding by 83 bps to 16.3%Bed capacity increased by 20% in FY26 to 3,610 beds, reaching 3,960 beds as of April 2026Strong liquidity position with INR 5,509 mn in cash and equivalents against negligible term debt of INR 282 mnSignificant operational improvement with debtor days reducing to 129 days from 161 days in the previous year
👀 கவனிக்க வேண்டியவை
Investors should note the company's successful balance of aggressive capacity expansion with improving profitability and debt reduction. The stock remains a strong growth play in the healthcare sector as new facilities begin contributing to the bottom line.
⚠️இந்தத் தளம் எவ்வாறு உருவாக்கப்படுகிறது: சந்தைத் தரவுப் பக்கங்கள் NSE/BSE வெளியீடுகள் மற்றும் நிறுவனங்களின் தாக்கல்களிலிருந்து தானாகக் கணக்கிடப்படுகின்றன; செய்திக் கட்டுரைகளும் அறிவிப்புப் பகுப்பாய்வுகளும் AI உதவியுடன் எழுதப்படுகின்றன, மனித மேற்பார்வையுடன்: AI உருவாக்குவதை எங்கள் ஆசிரியர்கள் மதிப்பாய்வு செய்கின்றனர். இரண்டிலும் பிழைகள் இருக்கலாம். எந்தவொரு முதலீட்டு முடிவுக்கு முன்பும் அசல் மூலங்களில் சரிபார்க்கவும். முதலீட்டு ஆலோசனை அல்ல; Flash Finance SEBI-பதிவு பெற்றது அல்ல. நாங்கள் AI-ஐ எவ்வாறு பயன்படுத்துகிறோம்
🎁 ஆரம்பகால ஆதரவாளர்களுக்கு மட்டும் · குறுகிய கால சலுகை
எங்கள் AI பங்குச் சந்தை பகுப்பாய்வு: டெலிகிராம், வாட்ஸ்அப்பில் இலவசம்
⚡ 3500+ நிறுவனங்களை நாங்கள் உடனுக்குடன் கண்காணிக்கிறோம். NSE-யில் ஒரு நிறுவன அறிவிப்பு வெளியானதுமே, எங்கள் AI அதைப் படித்து, சுருக்கி, அதன் தாக்கத்தைச் சில நொடிகளில் உங்களுக்குச் சொல்கிறது.
இதுபோன்ற AI பகுப்பாய்வுக்குக் கட்டணத் தளங்கள் ஆண்டுக்கு ₹1,00,000-க்கும் மேல் வசூலிக்கின்றன. எங்கள் சேனல்களில் இது இலவசம்.
